title: Osteoinductivity potential of rhBMP-2 associated with two carriers in different dosages.
abstract: The objective of this study was to evaluate bone formation after application of different doses of recombinant human bone morphogenetic protein-2 (rhBMP-2) combined with monoolein or poloxamer gels, in critical bone defects of rats. Forty-five Wistar rats were divided into nine treatment groups with five animals each: I: application of 1 µg rhBMP-2 + monoolein; II: 3 µg rhBMP-2 + monoolein; III: 7 µg rhBMP-2 + monoolein; IV: 1 µg rhBMP-2 + poloxamer; V: 3 µg rhBMP-2 + poloxamer; VI: 7 µg rhBMP-2 + poloxamer; VII: monoolein only; VIII: poloxamer only; and IX: critical bone defect only. A critical-sized defect of 6 mm diameter was produced in the left parietal bone and it was filled with gels of the above mentioned treatments. After 2 weeks, the calvarial bones were removed for histological processing. Bone formation in the groups that received poloxamer gel and rhBMP-2 was not significantly different from the control group (IX). Groups receiving monoolein and rhBMP-2 (1 and 3 µg) and those that received only the carriers (VII and VIII) had less bone formation in relation to the control. The association of rhBMP-2 to both poloxamer and monoolein did not exhibit any significant differentiation in bone formation in comparison with the control group.
authors.affiliation: Department of Morphology, Oral Medicine and Physiology, Faculty of Dentistry, University of São Paulo, Av. Café S/N, Bairro: Monte Alegre, Ribeirão Preto, São Paulo 14040-904, Brazil.
authors.forename: Priscilla Maria Fernandes
authors.initials: PM
authors.lastname: Abdala
authors.forename: Mamie Mizusaki
authors.initials: MM
authors.lastname: Iyomasa
authors.forename: Sandra
authors.initials: S
authors.lastname: Sato
authors.forename: Maria Vitória Lopes Badra
authors.initials: MV
authors.lastname: Bentley
authors.forename: Dimitrius Leonardo
authors.initials: DL
authors.lastname: Pitol
authors.forename: Simone Cecílio Hallak
authors.initials: SC
authors.lastname: Regalo
authors.forename: Selma
authors.initials: S
authors.lastname: Siéssere
authors.forename: João Paulo Mardegan
authors.initials: JP
authors.lastname: Issa
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage* / Q000494:pharmacology*; D005989:Glycerides / Q000008:administration & dosage* / Q000494:pharmacology*; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D020442:Poloxamer / Q000008:administration & dosage* / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000494:pharmacology*; D012886:Skull / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D005989:Glycerides; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D020442:Poloxamer; C005953:monoolein